Innate Pharma Reports Full-Year 2025 Financial Results and Business Update
ByAinvest
Thursday, Mar 26, 2026 2:01 am ET1min read
IPHA--
Innate Pharma reported its 2025 financial results and business update. Lacutamab's confirmatory Phase 3 trial in cutaneous T-cell lymphoma is planned for H2 2026, subject to non-dilutive financing options. IPH4502 (Nectin-4 ADC) shows preliminary anti-tumor activity and a favorable safety profile. The Monalizumab PACIFIC-9 Phase 3 trial continues to advance toward a planned H2 2026 data readout. IPH5201 (anti-CD39 antibody) interim results have been selected for an oral presentation at the AACR Annual Meeting 2026. The company has a cash position of €44.8 million as of December 31, 2025, with an anticipated cash runway until the end of Q3 2026.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet